Characteristics of Short-Term Survivors With <i>ALK</i> or <i>ROS1</i>-Altered Metastatic NSCLC.

ABSTRACT:

Introduction

The prognostic significance of baseline and on-treatment brain and liver metastasis in ALK+ or ROS1+ metastatic NSCLC (mNSCLC) remains unclear. As we consider intensification strategies, it is critical to identify factors that predict high-risk disease.

Methods

Clinical characteristics and outcomes were abstracted from the electronic medical records of patients with ALK+ or ROS1+ mNSCLC. Baseline characteristics and the cumulative incidence (CI) of brain and liver metastases were compared (≥2-year survivors versus <2-year; pre-2017 versus post-2017). Multivariable Cox proportional hazard models were used to evaluate the association between factors and overall survival, and multivariable logistic regression models were used for the odd

SUBMITTER: Liu KL 

PROVIDER: S-EPMC12605057 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature